Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib plus platinum-pemetrexed first-line therapy for metastatic EGFR atypical-mutant NSCLC
2024-516790-78-00Phase 2Authorised
- Sponsor
- Heidelberg University
- Start
- Mar 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib, pemetrexed, carboplatin and cisplatin in non-small cell lung cancer (NSCLC), sponsored by Heidelberg University. Primary endpoint: Progression-free survival rate at 12 months. Planned start Mar 2025; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-516790-78-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516790-78-00.